Abstract
In March 2020, the U.S. Food and Drug Administration (FDA) required a Black Box Warning for montelukast due to serious mental health side effects. We hypothesized that the warning would lead to an overall decrease in reports of mental health symptoms and disorders related to montelukast use among pediatric patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
